Anticoagulation effect of nalimostat at different doses in the treatment of hemodialysis patients
不同剂量甲磺酸萘莫司他在血液透析患者治疗中的抗凝效果

摘要

目的 本研究旨在评估甲磺酸萘莫司他在不同剂量下对血液透析患者抗凝疗效的影响。方法 于2023年1月至2024年12月，选取本院80例维持性血液透析患者，随机分成两组：观察组（40例，甲磺酸萘莫司他剂量为20ml/h）和对照组（40例，甲磺酸萘莫司他剂量为10ml/h）。所有患者均接受常规血液透析治疗，并在透析过程中使用甲磺酸萘莫司他进行抗凝。观察并记录两组患者的抗凝效果、凝血指标变化及不良反应发生率。结果 观察组患者的抗凝有效率高于对照组（P＜0.05）。透析结束后，观察组在活化部分凝血活酶时间（APTT）、凝血酶时间（TT）等凝血参数上均表现更佳（P＜0.05）。且观察组并发症发生率更低（P＜0.05）。结论 血液透析治疗中，20ml/h甲磺酸萘莫司他剂量相较于10ml/h展现出更优的抗凝效能，且安全性更高，值得临床推广应用。

Abstract

Objective This study aims to evaluate the effect of pranostat mesylate on the anticoagulant efficacy in hemodialysis patients at different doses.
Methods From January 2023 to December 2024,80 maintenance hemodialysis patients in our hospital were randomly divided into two groups: observation group (40 patients, naphthalostat dose 20ml / h) and control group (40 patients, naphthalostat methyllate dose 10ml / h). All patients were treated with routine hemodialysis and underwent anticoagulation with nlimostat mesylate during dialysis. The coagulation effect, changes in coagulation index and incidence of adverse reactions were observed and recorded in both groups.
Results More effective in the observation group than in the control group (P＜0.05). After dialysis, the observation group performed better in coagulation parameters such as activated partial thrombin time (APTT) and thrombin time (TT) (P＜0.05). And the complication rate was lower in the observation group (P＜0.05).
Conclusion   In hemodialysis treatment, the dose of 20ml / h showed better anticoagulant efficacy and higher safety compared with 10ml / h, which is worthy of clinical application.